Review Article

Etiology, Epidemiology and Histopathology of Bladder Cancer: A Review

Hameda Abd Al-Mahdi Ghazi [1,*], Zahraa Hamid Mohan Al-Gawwam[1], Rasha Hamzah Abdulhussein[2], Shahlaa K.H. Chabuk[2]

[1] Department of Anatomy, Hammurabi College of Medicine, University of Babylon, Hilla 51002, Iraq

[2] Department of Physiology and Medical Physics, Hammurabi College of Medicine, University of Babylon, Hilla 51002, Iraq

* Corresponding author: hameda.asad@uobabylon.edu.iq

Submission: April 14, 2025 Accepted: May 26, 2025 Published: June 30, 2025

Abstract

Bladder cancer is mostly urothelial carcinoma and remains one of the large health burdens globally; its etiology is very complex and results from interplay of various genetic, environmental, and lifestyle factors. It makes the diagnosis and management of bladder cancer very challenging due to its heterogeneity and sometimes complex histopathology. Recent advancements in molecular biology have so far revealed extremely pertinent aspects concerning the histopathology of bladder cancer that would necessitate a shift in emphasis within existing classification paradigms. The drawing-up of molecular insights into histopathological evaluations tallies with enhanced classification systems that ought to lead the same further into personalized treatment approaches. Research in this direction will not only bridge the existing lacunae but also pave the way for better management strategies for patients with bladder cancer. This literature review will try to put together what has been found in current studies about why bladder cancer happens, point out where there is not enough information, and recommend ways to look further into this. At the same time, it brings together new results on the histopathology of bladder cancer, stressing its molecular foundations, histological types, and the relationship between molecular aspects and histopathological assessment. it also brings together recent findings on bladder cancer epidemiology, noting risk factors, regional variations, and consequences for public health intervention.

Keyword: Bladder cancer, Urothelial carcinoma, Etiology, Epidemiology, Histopathology, Risk factors.

Introduction

Bladder cancer, mostly urothelial carcinoma, remains one of the major health concerns worldwide with complicated etiology due to the interplay of countless genetic, environmental, and lifestyle factors. The majority of bladder cancers begin in the cells that line the inside of the bladder (urothelial cells). These places also contain these cells in both kidneys and their connecting tubes (ureters) needed to convey urine from the kidneys to the bladder. Even though urothelial carcinoma may occur in these two other locations within the body, bladder urothelial carcinoma is far more common. Fortunately, most cases are diagnosed when they are at an early stage and highly amenable to treatment. This will necessitate frequent surveillance for recurrence even if found at an initial stage and treated successfully since even such tumors have a propensity for recurrence [1]. Bladder cancer etiology has not left some significant knowledge gaps. For example, the interplay between genetic predispositions and environmental exposures is not well established. Future research should focus on descriptive longitudinal studies that explore how these two sets of factors interact over time. Also, what is required is more comprehensive research on the

biological mechanisms through which lifestyle factors affect bladder cancer risk [2]. If it could be understood how modifiable risk factors act upon molecular pathways, then perhaps even better prevention strategies could be developed. Finally, the gender and ethnic demographic effects on bladder cancer etiology require further exploration. More specific prevention and treatment approaches can thus be developed to improve outcomes in various patient populations [3].

There are rather unserious shortcomings in the histopathology of bladder cancer. One major direction for future investigation should be long-term studies relating molecular changes to histopathological changes over time, which would help in better understanding tumor evolution and provide guidance for treatment approaches [4]. In addition, although the integration of molecular data into histopathological assessments bears good potential, standardized protocols for such integrations have yet to be developed. Future research should aim at forming guidelines for integrating histopathological evaluation with molecular profiling so that diagnostic accuracy and treatment outcomes can be ameliorated. The rest should also bear prioritization in terms of exploration for less common histological variants and their molecular features. Understanding the specifics of these variants will be crucial in developing targeted therapies and improving patient management [5].

Wong et al. [6] reported the organoid culture systems developed for bladder cancer in their recent research. Through these systems, molecular characteristics and mutations related to bladder cancer can be studied. Organoid cultures have great potential to deepen our knowledge about the etiology of bladder cancer and bring forth personalized treatment strategies. Additionally, it highlights a novel application of urease-powered nanomotors for targeted therapies that may uncover the distinctive metabolic microenvironment of bladder carcinoma cells by Gontero et al. [7]. These unique features of the bladder carcinoma cell must be understood to design appropriate therapeutic interventions.

Though much has been said about bladder cancer epidemiology, knowledge gaps hold. For example, the association between smoking and bladder cancer is common in narratives. However, more detailed research is needed that examines how genetic predispositions interact with environmental exposures across different populations. Also, the effects of lifestyle choices on the risk of developing bladder cancer are less explored; these include diet and physical activity [8].

Future studies should also concentrate on crafting prevention plans that cater to the specifics of an area, tackling local risk factors like schistosomiasis in regions where it is common and job dangers in places of work. Longitudinal studies to keep track of changes in bladder cancer incidence and survival over time will be key in assessing how well public health actions are working [9].

Epidemiology

Bladder cancer constitutes about 3% of total cancer cases worldwide, with greater incidence in developed nations. The age distribution of cases demonstrates that 90% of them are above 55 years old, which confirms the importance of age as a major risk factor [10]. In several countries, particularly those located within demographic transition and urbanization trajectories, like China, an increased incidence of bladder cancer is observed as an expression of modified lifestyle habits [11]. In Egypt, out of all

cancer cases, 6.9% are due to bladder cancer; this expresses a rising worry in regions where large changes in both lifestyle and demographics take place [12].

Though the incidence of bladder cancer is on the rise, fatality rates in some areas have taken a contrasting downward path and this is possibly due to progress in treatment as well as early detection [13, 14]. The fact that more cases are being diagnosed implies that improvements in access to healthcare as well as management of cancer are resulting in positive outcomes when it comes to survival rates so that divergence exists now between incidence and mortality [14].

Bladder cancer is not distributed the same way in the world. In developed countries, higher incidence rates go hand in hand with socioeconomic status levels, which find expression in a positive association with the Human Development Index (HDI) [14]. On the other hand, low- and middle-income countries may underreport cases of bladder cancer and, thus, the real burden of disease may remain concealed. This difference requires specific public health measures that consider regional differences in bladder cancer risk factors as well as accessibility to healthcare services [11]. The bladder cancer review emphasizes the need for holistic cancer care that includes lifestyle changes like diet and smoking [3]. Also, easy find programs especially in at-risk groups are key to better results and lower bladder cancer death rates [15].

Risk Factors

The considerable epidemiological variation that characterizes bladder cancer is due to its risk factors that involve tobacco use, occupational exposure, and general lifestyle choices. The paper by Cumberbatch et al. [3] reviewed a number of publications and reported findings that realized the incidence of bladder cancer as a result of several modifiable factors-smoking, obesity, and some dietary habits. In their presentation, however, good targeted prevention focusing on these factors would yield substantial reductions in cases of bladder cancer [16].

Tobacco smoking holds a very significant place, as Zaorsky et al. [17] have already pointed out; it is the leading cause of bladder cancer. Other important factors have been considered to be occupational exposure to chemical agents and environmental toxins. The present review has highlighted that such modifiable risk factors, over which public health can exert intervention, give full access to reduction in the incidence of bladder cancer.

General risk factors for bladder cancer reveal some similarities with other tumors, especially the major link with smoking. It has been reported that the risk for smokers to develop bladder cancer compared to non-smokers is 4.06 [18, 19]. The large population-attributable risk of smoking highlightss in smusts a need for strong tobacco control policies to be central in the bladder cancer prevention strategy [3].

Insights into Pathogenesis

Molecular biology shed results on the genetic basis of bladder cancer. According to Knowles and Hurst [20], genomic characterization has also revealed a high mutational burden in bladder cancer, which may imply an intricate imbalance of genetic factors involved in its pathogenesis. Specifically mutated genes like TP53 and FGFR3 give information about the molecular grounds of bladder cancer and show corresponding vulnerabilities in therapy.

The work of Chen et al. [21] reports for the first time the involvement of 5-methylcytosine in mRNA stabilization, thus promoting pathogenesis in bladder cancer. This finding

indeed puts epigenetic modifications at the very core of cancer development and suggests that metabolic pathways be explored concerning the etiology of bladder cancer. Dobruch et al. [22] offers a joint review on gender differences in bladder cancer, which sheds light on their disparate etiology, biology, and outcomes. It thus calls for research that includes demographic factors as covariates so that differential responses to risk factors and treatment modalities may be identified [23].

Role of Life style

The role of lifestyle factors in the risk of bladder cancer is well supported by Friedenreich et al. [24] in their review on epidemiological evidence regarding physical activity, obesity, and sedentary behavior as it relates to the etiology of cancer. In other words, their study adds to bladder cancer urging that more physical activity in life could make a good preventive measure about this type of cancer and hence reinforce the importance of lifestyle modifications. Another very good look at lifestyle factors by Jubber et al. [25] also confirmed the role of exercise and obesity in bladder cancer made sure to state that these require public health campaigning for promoting healthier lifestyles as a pathway for cancer prevention.

Molecular Classification and Histopathology

The consensus molecular classification proposed by Kamoun et al. [26] integrates molecular features with the histopathology of muscle-invasive bladder cancer. According to their study, mutations occur in cyclical and chromatin-regulatory genes which drive the histopathological heterogeneity of bladder cancer. These also split expression into types and subtypes that may correspond to papillary-like and basal/squamous-like tumors, implying that m application of histopathological classification should adapt to incorporate these molecular features [27]. Subtype tumors have identified therapeutic targets, representing an avenue through which personalized treatment can be aligned with histopathological findings [28].

In the same way, Lerner et al. [29] did a thorough molecular description of urothelial bladder carcinoma, showing five different tumor-cell types based on gene expression and immunohistochemistry. This categorization shows the diversity of urothelial carcinoma and implies that standard histopathological reviews might not fully reflect the complexity of bladder cancer. The idea of false-differentiation in tumors, where look may hide different molecular activities, stresses the need for combining molecular data with histopathological evaluations for correct prognostic details.

Building on these findings [1] compared global mRNA classification and tumor-cell phenotype classification, reinforcing the idea that molecular profiling can enhance the understanding of histopathological characteristics. This integration of molecular pathology with histopathology is pivotal for improving classification and treatment strategies, particularly for muscle-invasive bladder cancer [30].

Histological Variants of Bladder Cancer

Bladder cancer presents with multiple histological variants that greatly influence prognosis and treatment. Variants that have low general frequency but high clinical significance should be carefully considered in diagnosis, particularly plasmacytoid carcinoma which has aggressive behavior and distinct molecular features [31]. Key histopathological features of plasmacytoid carcinoma were further explained by López-Beltran et al. [30], which puts the role of E-cadherin and CK20 expression in this

diagnosis. Such information, as described above, urges pathologists to stay educated on the changing classifications for proper diagnosis leading to proper management.

The contribution of molecular markers to the comprehension of histopathological features is further sustained by Thomsen et al. [5], who talk about the enhanced expression of FTO in bladder tumor tissues. It is from these findings that they suggest molecular markers like FTO should be integrated into histopathological evaluations for prognostic assessments so as to bridge the gap between histopathology and molecular biology [32].

Conclusions

Bladder cancer results from a combination of genetic, environmental, and lifestyle practices. Although the contribution of these factors has been well studied, research should continue bridge the gap in knowledge about them and how best to prevent or treat the disease. Future studies will have to bring together molecular insights with epidemiological data to create a more complete picture of bladder cancer etiology. A new field opened up in the understanding of bladder cancer through an intersection between histopathology and molecular biology. The integration of molecular insights into histopathology is needed for upgrading classification systems that can also be used to personalize treatment approaches. Research in this field will not only fill existing gaps in knowledge but also lead toward better management options for patients with bladder cancer. The epidemiology of bladder cancer is marked by the complex interaction of risk factors, demographic trends, and later differences. These dynamics must be well understood to ensure the establishment of effective targeted prevention and treatment strategies. Further research should be carried out to fill the present gaps in knowledge and thus tailor public health initiatives to fight bladder cancer, which is becoming a major global burden.

Conflict of interest

None

References

[1] Sjödahl G, Eriksson P, Liedberg F, Höglund M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. *J Pathol.* 2017;242(1):113–25. doi:10.1002/path.4886

[2] Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. *Nat Rev Gastroenterol Hepatol*. 2019;16(12):713–32. doi:10.1038/s41575-019-0189-8

[3] Cumberbatch M, Jubber I, Black P, Esperto F, Figueroa J, Kamat A, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. *Eur Urol.* 2018;74(6):784–95. doi:10.1016/j.eururo.2018.09.001

[4] Patel V, Oh W, Galsky M. Treatment of muscle-invasive and advanced bladder cancer in 2020. *CA Cancer J Clin.* 2020;70(5):404–23. doi:10.3322/caac.21631

[5] Thomsen MBH, Nordentoft I, Lamy P, Vang S, Reinert L, Mapendano CK, et al. Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. *Sci Rep.* 2017;7:11702. doi:10.1038/s41598-017-11291-0

[6] Wong M, Fung FDH, Leung C, Cheung WWL, Goggins W, Ng C. The global

epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. *Sci Rep.* 2018;8:1129. doi:10.1038/s41598-018-19199-z

[7] Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. *Eur Urol.* 2015;67(1):74–82. doi:10.1016/j.eururo.2014.06.040

[8] Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol.* 2013;63(2):234–41. doi:10.1016/j.eururo.2012.07.033

[9] Mullenders J, de Jongh E, Brousali A, Roosen M, Blom JPA, Begthel H, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. *Proc Natl Acad Sci U S A.* 2019;116(10):4567–74. doi:10.1073/pnas.1803595116

[10] Leiter A, Veluswamy R, Wisnivesky J. The global burden of lung cancer: current status and future trends. *Nat Rev Clin Oncol.* 2023;20(10):624–39. doi:10.1038/s41571-023-00798-3

[11] Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. *Chin Med J (Engl).* 2022;135(6):584–90. doi:10.1097/CM9.0000000000002108

[12] Huang DQ, El-Serag H, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol.* 2020;18(4):223–38. doi:10.1038/s41575-020-00381-6

[13] Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. *Eur Urol.* 2017;71(1):96–108. doi:10.1016/j.eururo.2016.06.010

[14] Thrift A, Wenker T, El-Serag H. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. *Nat Rev Clin Oncol.* 2023;20(6):338–49. doi:10.1038/s41571-023-00747-0

[15] Saginala K, Barsouk A, Aluru J, Rawla P, Padala S, Barsouk A. Epidemiology of bladder cancer. *Med Sci (Basel).* 2020;8(1):15. doi:10.3390/medsci8010015

[16] Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. *Prz Gastroenterol.* 2018;14(1):26–38. doi:10.5114/pg.2018.80001

[17] Zaorsky NG, Churilla T, Egleston B, Fisher S, Ridge JA, Horwitz E, et al. Causes of death among cancer patients. *Ann Oncol.* 2017;28(2):400–7. doi:10.1093/annonc/mdw604

[18] Freedman N, Silverman D, Hollenbeck A, Schatzkin A, Abnet C. Association between smoking and risk of bladder cancer among men and women. *JAMA.* 2011;306(7):737–45. doi:10.1001/jama.2011.1142

[19] Ibrahim AS, Khaled H, Mikhail N, Baraka H, Kamel H. Cancer incidence in Egypt: results of the National Population-Based Cancer Registry Program. *J Cancer Epidemiol.* 2014;2014:437971. doi:10.1155/2014/437971

[20] Knowles M, Hurst C. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. *Nat Rev Cancer.* 2015;15(1):25–41. doi:10.1038/nrc3817

[21] Chen X, Li A, Sun BF, Yang Y, Han Y, Yuan X, et al. 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. *Nat Cell Biol.* 2019;21(8):978–90. doi:10.1038/s41556-019-0361-y

[22] Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon A, Resnick M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. *Eur Urol.* 2016;69(2):300–10. doi:10.1016/j.eururo.2015.08.037

[23] Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology directed therapy for advanced bladder cancer. *Nat Rev Urol.* 2019;16(8):465–83. doi:10.1038/s41585-019-0208-0

[24] Friedenreich C, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. *Mol Oncol.* 2021;15(3):790–800. doi:10.1002/1878-0261.12772

[25] Jubber I, Ong S, Bukavina L, Black P, Compérat E, Kamat A, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. *Eur Urol.* 2023;84(5):784–803. doi:10.1016/j.eururo.2023.03.029

[26] Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. *Eur Urol.* 2020;77(4):420–33. doi:10.1016/j.eururo.2019.09.006

[27] Sylvester R, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, et al. EAU prognostic factor risk groups for non–muscle-invasive bladder cancer incorporating WHO 2004/2016 and 1973 classification systems: an update from the EAU NMIBC Guidelines Panel. *Eur Urol.* 2021;79(4):480–8. doi:10.1016/j.eururo.2020.12.033

[28] McConkey D, Choi W. Molecular subtypes of bladder cancer. *Curr Oncol Rep.* 2018;20(10):77. doi:10.1007/s11912-018-0727-5

[29] Lerner S, Kwiatkowski D, Weinstein J, Creighton CJ, Akbani R, Kim J, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature.* 2014;507(7492):315–22. doi:10.1038/nature12965

[30] López-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini M, Cheng L. Variants and new entities of bladder cancer. *Histopathology.* 2019;74(1):77–96. doi:10.1111/his.13752

[31] Moschini M, D'Andrea D, Korn S, Irmak Y, Soria F, Compérat E, et al. Characteristics and clinical significance of histological variants of bladder cancer. *Nat Rev Urol.* 2017;14(11):651–68. doi:10.1038/nrurol.2017.125

[32] Uhlenhopp D, Then E, Sunkara T, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. *Clin J Gastroenterol.* 2020;13(6):1010–21. doi:10.1007/s12328-020-01237-x